Altimmune Inc
ALT4.110USD
+0.170+4.31%
收盘 11/07, 16:00（美东）报价延迟15分钟
392.91M总市值
亏损市盈率 TTM
关于 Altimmune Inc 公司
Altimmune, Inc. 是一家临床阶段的生物制药公司，专注于开发肥胖和肝病的治疗方法。该公司的主要候选产品 pemvidutide 是一种 GLP-1/胰高血糖素双受体激动剂，正在开发用于治疗肥胖和代谢功能障碍相关脂肪性肝炎 (MASH)。该公司已完成 MOMENTUM II 期肥胖试验，并正在进行 IMPACT IIb 期 MASH 试验的研究。该公司还在开发 HepTcell，这是一种针对慢性感染乙型肝炎病毒 (HBV) 患者的免疫治疗候选产品。该公司已完成 HepTcell II 期临床试验的招募。其候选产品基于其专有平台技术，例如基于 EuPort 的肽技术和合成肽技术 - Densigen。该公司的全资子公司包括 Altimmune, LLC、Altimmune UK, Limited、Spitfire Pharma, LLC 和 Altimmune AU Pty, Limited。
Altimmune Inc简介
公司代码ALT
公司名称Altimmune Inc
上市日期Oct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
员工数量59
证券类型Ordinary Share
年结日Oct 06
公司地址910 Clopper Road
城市GAITHERSBURG
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编20878-1361
电话12406541450
网址https://altimmune.com/
公司代码ALT
上市日期Oct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Altimmune Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Ms. Linda M. Richardson
Ms. Linda M. Richardson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Chairman of the Board
Chairman of the Board
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月4日 周二
更新时间: 11月4日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Investment Management (US)
2.64%
Tang Capital Management, LLC
2.64%
Geode Capital Management, L.L.C.
1.86%
其他
81.23%
持股股东
持股股东
占比
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Investment Management (US)
2.64%
Tang Capital Management, LLC
2.64%
Geode Capital Management, L.L.C.
1.86%
其他
81.23%
股东类型
持股股东
占比
Investment Advisor
20.68%
Investment Advisor/Hedge Fund
9.49%
Hedge Fund
7.78%
Research Firm
3.16%
Individual Investor
0.73%
Bank and Trust
0.38%
Pension Fund
0.05%
Insurance Company
0.03%
其他
57.70%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
405
38.06M
36.57%
-11.64M
2025Q2
413
40.03M
49.36%
-12.37M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
5.17M
5.85%
+772.36K
+17.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.75M
6.52%
+223.90K
+4.05%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.12%
-637.93K
-18.81%
Jun 30, 2025
Tang Capital Management, LLC
2.75M
3.12%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.19%
+229.00K
+13.42%
Jun 30, 2025
Susquehanna International Group, LLP
1.62M
1.84%
+543.68K
+50.53%
Jun 30, 2025
Knoll Capital Management, LLC
1.12M
1.27%
--
--
Jun 30, 2025
Caption Management, LLC
980.78K
1.11%
+941.92K
+2423.62%
Jun 30, 2025
BofA Global Research (US)
716.02K
0.81%
+435.47K
+155.22%
Jun 30, 2025
UBS Financial Services, Inc.
633.56K
0.72%
-94.60K
-12.99%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.48%
Virtus LifeSci Biotech Clinical Trials ETF
0.38%
SPDR S&P Biotech ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
Fidelity Enhanced Small Cap ETF
0.06%
iShares Micro-Cap ETF
0.06%
iShares Biotechnology ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Russell 2000 Growth ETF
0.02%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.48%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.38%
SPDR S&P Biotech ETF
占比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.08%
Fidelity Enhanced Small Cap ETF
占比0.06%
iShares Micro-Cap ETF
占比0.06%
iShares Biotechnology ETF
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
iShares Russell 2000 Growth ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
